Myriad Genetics' Shares Rise as Reimbursement Concerns Ease

Shares of molecular diagnostics company Myriad Genetics jumped 13 percent in morning trading, after the company said the proposed cut in Medicare reimbursement rates for one of its tests was the result of a clerical error.
Reuters